Reuters |
US FDA approves Glaxo, Theravance's Breo Ellipta asthma drug
Reuters (Reuters) – The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA declined to approve Breo for younger … GlaxoSmithKline plc (ADR) Gets FDA Approval For Breo Ellipta To Treat Asthma … FDA Okays Breo Ellipta for Asthma in Adults Glaxo Wins U.S. Approval to Sell Breo Only to Adults With Asthma |
View full post on asthma – Google News